InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (3 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
3
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Stengone Carmine N., Chief Executive Officer. Insider active across 2 companies, notably Contineum Therapeutics, Inc.. In total, 10 disclosures have been recorded. Breakdown: 1 buy · 3 sells. Total volume traded: €74k. History available since 11 September 2024. The latest transaction was filed on 3 August 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Stengone Carmine N.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations10 total
2,500 shares@ US$1.01Class A Common StockSEC:0001628280-26-052031:0
2,500 shares@ US$16.0116Class A Common StockSEC:0001628280-26-052031:1
2,500 shares@ US$1.010.0005% mcap4.7% of flowClass A Common StockSEC:0001628280-26-047710:0
2,500 shares@ US$16.000.0074% mcap75.1% of flowClass A Common StockSEC:0001628280-26-047710:1
7,500 sharesClass A Common StockSEC:0001628280-26-046653:0
2,500 sharesClass A Common StockSEC:0001628280-26-046653:1
10,000 sharesClass A Common StockSEC:0001628280-26-046653:2
4,400 shares@ US$1.260.0011% mcap50.0% of flowClass A Common StockSEC:0001437749-26-005892:0
400 shares@ US$1.261.0% of flowClass A Common StockSEC:0001437749-26-004126:0
1,250 shares@ US$3.68100.0% of flowCommon StockSEC:0001372514-24-000115:0
Canonical exit: 10 Dec 2024 (T+90)
10 of 10 declarations
About Stengone Carmine N.
Carmine N. Stengone is the Chief Executive Officer of Contineum Therapeutics, Inc. He is responsible for the strategic and operational direction of the company. His expertise in the biotechnology sector is essential for the development of new therapeutic solutions.
